OBJECTIVES: To describe the adherence and patient reported outcomes (PROs) of rheumatoid arthritis (RA) patients taking biologic drugs enrolled in a specialty pharmacy (SP) program. METHODS: A retrospective analysis of pharmacy claims and PRO data for RA patients enrolled in a SP program and receiving biologic drugs from 12/1/2011 through 10/31/2013 was conducted.  Patients with a primary diagnosis of RA (ICD-9 CM: 714.xx) were included.  Only those with at least two pharmacy claims and those with a baseline and at least one follow-up of PRO measures were analyzed.  Patients who were <18 or ≥90 years of age, who switched drugs or who declined involvement were excluded.  Medication possession ratio (MPR) was used as a proxy for adherence and calculated based on pharmacy claims data.  PROs were collected via telephone and included pain and fatigue measured on a numeric rating scale (NRS, scale: 0-10), and functional status measured using the Health Assessment Questionnaire-II (HAQ-II, scale: 0-3).  Outcomes were collected at baseline and approximately every six months for the duration of the patients’ enrollment.  Descriptive statistics, Wilcoxon signed-rank, and correlations were used to analyze the data.  RESULTS: A total of 2,385 patients were included.  The mean age of patients was 54.80 years (±12.88) and 70.48% were female.  The average MPR for all patients was 86.47% (±15.14%) over an average of 403.89 days (±167.20).  Overall, 36.27% and 38.87% of patients had at least 1-point decrease on the pain NRS and fatigue NRS, respectively.  Any reduction in the HAQ-II score was observed in 46.79% of patients at follow-up, which was statistically significant (-0.065, p<0.001).  CONCLUSIONS: RA patients receiving biologic medications enrolled in a SP program had high therapy adherence and realized decreases in pain, fatigue and improvement in functional status from baseline.